FDA Expands Use for Ortho's VITROS HIV Combo Test: Menu Milestone for VITROS XT 7600 Integrated System

Publisher: The Insight Partners

Ortho Clinical Diagnostics, a global leader in vitro diagnostics, announced that it’s VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS HIV Combo test) was granted pre-market approval by the U.S. Food and Drug Administration for use on Ortho’s VITROS XT 7600 Integrated System in August 2019.

Ortho Clinical Diagnostics is among one of the global leader of in vitro diagnostics that serves the global clinical laboratory and immunohematology communities. The company serves hospitals, hospital networks, blood banks, and labs in more than 120 countries. Ortho's high-quality products and services enable healthcare professionals to make better-informed treatment decisions. With respect to the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit.

For more than 75 years, Ortho has pioneered life-impacting advances, from our earliest work in blood typing to the latest developments in laboratory systems. Scientific advances that have helped medical professionals diagnose conditions early and make better-informed treatment decisions.